Delphi panel to understand the real-world occurrence and management of ofatumumab injection-related reactions among healthcare providers of people with relapsing multiple sclerosis.

BACKGROUND

People with relapsing forms of multiple sclerosis (PwRMS) treated with ofatumumab, a fully human anti-CD20 monoclonal antibody, can experience local/systemic injection-related reactions (IRRs). However, data on the occurrence and management of local/systemic IRRs in real-world clinical settings are limited.

OBJECTIVE

This study aimed to better understand clinicians' perspectives regarding occurrence and management of local/systemic IRRs among PwRMS treated with ofatumumab in clinical practice.

METHODS

A panel of US-based neurologists and advanced practice providers experienced with ofatumumab therapy in PwRMS participated in a three-round online modified Delphi study. In round 1, participants completed a demographics survey and Delphi questionnaire on IRR management. In round 2, they attended a live webinar to obtain feedback on round 1 results. In round 3, they reviewed round 1 and 2 feedback and provided their final responses.

RESULTS

Forty participants (neurologists, n = 31; nurse practitioners, n = 5; and physician assistants, n = 4) completed all three rounds. Participants strongly agreed that local/systemic IRRs, regardless of severity, were unlikely with ofatumumab. Pre-/post-treatment of systemic IRRs was not uniformly required.

CONCLUSION

This study gives health care providers insight into the potential occurrence and management of IRRs with ofatumumab in the clinical practice setting.